Truvada Sales To Rise On EU Okay In HIV Prevention; UK Use Uncertain
Executive Summary
The EU’s approval of Gilead’s Truvada for pre-exposure prophylaxis makes it the first medicine licensed in Europe to reduce the risk of HIV transmission through sexual intercourse and puts pressure on Britain’s reluctant, cash-strapped National Health Service to provide public funding for the drug’s preventative use.
You may also be interested in...
ViiV Poised To Take HIV PrEP Injectable In Late-Stage Trials
ViiV Healthcare is set to start Phase III studies of its next-generation integrase inhibitor cabotegravir as a long-acting injectable for the prevention of HIV. The head-to-head study will compare it with Gilead’s market leading oral PrEP therapy Truvada in pre-exposure prohylaxis in both men and women.
Hepatitis C And PrEP Bring More Funding Headaches For NHS England
Drugs for hepatitis C and HIV prevention are causing funding problems for the NHS in England as court battles loom and innovation continues to bring more cost pressures.
France Leads Europe In Reimbursing Truvada For HIV Prophylaxis
Gilead Sciences' HIV drug Truvada is now being reimbursed in France for pre-exposure prophylaxis (PrEP) under a "temporary use recommendation" (RTU) that came into effect on Jan. 4. This is understood to be the first European country where Truvada can be officially prescribed and reimbursed for PrEP, an indication for which it has not yet received an EU marketing authorization.